VEGF Gene Therapy Fails to Improve Perfusion of Ische Advanced Coronary Disease: Results of the NORTHERN

Molecular Therapy 17, 1109-1115 DOI: 10.1038/mt.2009.70

Citation Report

#	Article	IF	CITATIONS
1	Modification of cardiovascular ion channels by gene therapy. Expert Review of Cardiovascular Therapy, 2009, 7, 939-953.	0.6	5
2	Spatiotemporal Delivery Strategies for Promoting Musculoskeletal Tissue Regeneration. Journal of Bone and Mineral Research, 2009, 24, 1507-1511.	3.1	45
3	Improved myocardial perfusion and cardiac function by controlled-release basic fibroblast growth factor using fibrin glue in a canine infarct model. Journal of Zhejiang University: Science B, 2010, 11, 895-904.	1.3	23
4	Hydrogels as a Platform for Stem Cell Delivery to the Heart. Congestive Heart Failure, 2010, 16, 132-135.	2.0	20
5	Systems biology of proâ€angiogenic therapies targeting the VEGF system. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2010, 2, 694-707.	6.6	80
6	Terapia gênica com VEGF para angiogênese na angina refratária: ensaio clÃnico fase I/II. Brazilian Journal of Cardiovascular Surgery, 2010, 25, 311-321.	0.2	28
7	Pharmacotherapy for end-stage coronary artery disease. Expert Opinion on Pharmacotherapy, 2010, 11, 207-213.	0.9	11
8	New therapies for the failing heart: trans-genes versus trans-cells. Translational Research, 2010, 156, 130-135.	2.2	7
9	Improving regenerating potential of the heart after myocardial infarction: Factor-based approach. Life Sciences, 2010, 86, 461-472.	2.0	30
10	New aspects in vascular gene therapy. Current Opinion in Pharmacology, 2010, 10, 208-211.	1.7	28
11	Diagnostic and prognostic value of 3D NOGA mapping in ischemic heart disease. Nature Reviews Cardiology, 2011, 8, 393-404.	6.1	77
12	Gene therapy for ischemic heart disease. Expert Opinion on Biological Therapy, 2011, 11, 723-737.	1.4	43
13	Intramyocardial plasmid-encoding human vascular endothelial growth factor A165/basic fibroblast growth factor therapy using percutaneous transcatheter approach in patients with refractory coronary artery disease (VIF-CAD). American Heart Journal, 2011, 161, 581-589.	1.2	87
14	Targeted Gene Therapy for the Treatment of Heart Failure. Canadian Journal of Cardiology, 2011, 27, 265-283.	0.8	35
15	Endothelial cell surface vimentin binding peptide induces angiogenesis under hypoxic/ischemic conditions. Microvascular Research, 2011, 82, 221-226.	1.1	18
16	Therapeutic angiogenesis for cardiovascular disease: biological context, challenges, prospects. Heart, 2011, 97, 181-189.	1.2	127
17	Gene therapy for ischemic heart disease. Journal of Molecular and Cellular Cardiology, 2011, 50, 742-750.	0.9	90
18	Advances in polymeric and inorganic vectors for nonviral nucleic acid delivery. Therapeutic Delivery, 2011. 2. 493-521.	1.2	49

#	Article	IF	CITATIONS
19	Therapeutic Angiogenesis for the Management of Refractory Angina: Current Concepts. Cardiovascular Therapeutics, 2011, 29, e1-e11.	1.1	19
20	Approaches in Gene Therapy of Cancer and Cardiovascular Diseases. , 0, , .		3
21	Therapy for Angina Pectoris Secondary to Coronary Disease. , 0, , .		0
22	Gene Therapy Targeting Inflammation in Atherosclerosis. Current Pharmaceutical Design, 2011, 17, 4210-4223.	0.9	42
23	Physiological and tissue-specific vectors for treatment of inherited diseases. Gene Therapy, 2011, 18, 117-127.	2.3	47
24	Progress and prospects: hurdles to cardiovascular gene therapy clinical trials. Gene Therapy, 2011, 18, 743-749.	2.3	54
25	Contrast Ultrasound and Targeted Microbubbles: Diagnostic and Therapeutic Applications for Angiogenesis. Journal of Cardiovascular Translational Research, 2011, 4, 404-415.	1.1	26
26	The evolution of heart gene delivery vectors. Journal of Gene Medicine, 2011, 13, 557-565.	1.4	47
27	Stem cells and growth factor delivery systems for cardiovascular disease. Journal of Biotechnology, 2011, 154, 291-297.	1.9	30
28	Myocardial therapeutic angiogenesis: a review of the state of development and future obstacles. Expert Review of Cardiovascular Therapy, 2011, 9, 1469-1479.	0.6	29
29	VEGF/SDF-1 promotes cardiac stem cell mobilization and myocardial repair in the infarcted heart. Cardiovascular Research, 2011, 91, 402-411.	1.8	223
30	Plasmid-mediated gene therapy for cardiovascular disease. Cardiovascular Research, 2011, 91, 565-576.	1.8	46
31	Fibroblast growth factor 9 delivery during angiogenesis produces durable, vasoresponsive microvessels wrapped by smooth muscle cells. Nature Biotechnology, 2011, 29, 421-427.	9.4	107
32	Therapeutic Option of Plasmid-DNA Based Gene Transfer. Current Topics in Medicinal Chemistry, 2012, 12, 1630-1637.	1.0	24
33	Double-Blinded, Placebo-Controlled, Randomized Gene Therapy Using Surgery for Vector Delivery. Human Gene Therapy, 2012, 23, 438-441.	1.4	11
34	Scaffold-Based Transplantation of Vascular Endothelial Growth Factor—Overexpressing Stem Cells Leads to Neovascularization in Ischemic Myocardium but Did Not Show a Functional Regenerative Effect. ASAIO Journal, 2012, 58, 268-274.	0.9	9
35	Adjuvant early and late cardioprotective therapy: access to the heart. Cardiovascular Research, 2012, 94, 226-236.	1.8	6
36	From Gene to Epigene-Based Therapies Targeting the Vascular Endothelium. Current Vascular Pharmacology, 2012, 10, 125-137.	0.8	4

#	Article	IF	CITATIONS
37	Pro- and anti-angiogenic therapy and atherosclerosis with special emphasis on vascular endothelial growth factors. Expert Opinion on Biological Therapy, 2012, 12, 79-92.	1.4	28
38	Contrast Ultrasound and Targeted Microbubbles: Diagnostic and Therapeutic Applications in Progressive Diabetic Nephropathy. Seminars in Nephrology, 2012, 32, 494-504.	0.6	10
39	10-year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb. Gene Therapy, 2012, 19, 392-395.	2.3	71
40	Incidence and clinical significance of cardiac biomarker elevation during stem cell mobilization, apheresis, and intramyocardial delivery: An analysis from ACT34-CMI. American Heart Journal, 2012, 164, 689-697.e3.	1.2	14
41	Sustained Improvement in Perfusion and Flow Reserve After Temporally Separated Delivery of Vascular Endothelial Growth Factor and Angiopoietin-1 Plasmid Deoxyribonucleic Acid. Journal of the American College of Cardiology, 2012, 59, 1320-1328.	1.2	33
42	Novel Approaches to Deliver Molecular Therapeutics in Cardiac Disease Using Adeno-Associated Virus Vectors. , 2012, , 391-458.		1
43	Anti-Thymocyte Globulin Induces Neoangiogenesis and Preserves Cardiac Function after Experimental Myocardial Infarction. PLoS ONE, 2012, 7, e52101.	1.1	17
44	G-CSF Induced Arteriogenesis in Humans: Molecular Insights into a Randomized Controlled Trial. Current Vascular Pharmacology, 2012, 11, 38-46.	0.8	1
45	Angiopoietin-1-expressing adipose stem cells genetically modified with baculovirus nanocomplex: investigation in rat heart with acute infarction. International Journal of Nanomedicine, 2012, 7, 663.	3.3	25
46	Nonviral gene therapy targeting cardiovascular system. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 303, H629-H638.	1.5	48
47	Effect of vascular endothelial growth factor gene transfer on infarct size, left ventricular function and myocardial perfusion in sheep after 2 months of coronary artery occlusion. Journal of Gene Medicine, 2012, 14, 279-287.	1.4	11
48	VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond. Gene Therapy, 2012, 19, 622-629.	2.3	212
49	Therapeutic angiogenesis for myocardial ischemia revisited: basic biological concepts and focus on latest clinical trials. Angiogenesis, 2012, 15, 1-22.	3.7	116
50	Percutaneous Approaches for Efficient Cardiac Gene Delivery. Journal of Cardiovascular Translational Research, 2013, 6, 649-659.	1.1	28
51	Vascular endothelial growth factor in heart failure. Nature Reviews Cardiology, 2013, 10, 519-530.	6.1	191
52	Therapy for the Coronary Circulation. , 2013, , 247-266.		0
53	Coronary Vasculature. , 2013, , .		12
54	Combined VEGF gene transfer and erythropoietin in ovine reperfused myocardial infarction. International Journal of Cardiology, 2013, 165, 291-298.	0.8	3

#	Article	IF	CITATIONS
55	Gene Therapy to Stimulate Angiogenesis to Treat Diffuse Coronary Artery Disease. Human Gene Therapy, 2013, 24, 948-963.	1.4	28
56	Targeting Sarcoplasmic Reticulum Calcium ATPase by Gene Therapy. Human Gene Therapy, 2013, 24, 937-947.	1.4	23
57	Advances in Growth Factor Delivery for Therapeutic Angiogenesis. Journal of Vascular Research, 2013, 50, 35-51.	0.6	51
58	Gene targeting in ischemic heart disease and failure: Translational and clinical studies. Biochemical Pharmacology, 2013, 85, 1-11.	2.0	13
59	Highâ€dose plasmidâ€mediated VECF gene transfer is safe in patients with severe ischemic heart disease (Genesisâ€I). A phase I, openâ€label, twoâ€year followâ€up trial. Catheterization and Cardiovascular Interventions, 2013, 82, 899-906.	0.7	37
60	Cardiac Regeneration with Stem Cells. , 2013, , 65-112.		0
61	Safety of Direct Cardiac Administration of AdVEGF-All6A+, a Replication-Deficient Adenovirus Vector cDNA/Genomic Hybrid Expressing All Three Major Isoforms of Human Vascular Endothelial Growth Factor, to the Ischemic Myocardium of Rats. Human Gene Therapy Clinical Development, 2013, 24, 38-46.	3.2	15
62	Gene Therapy to Treat Cardiovascular Disease. Journal of the American Heart Association, 2013, 2, e000119.	1.6	55
63	Local Inhibition of MicroRNA-24 Improves Reparative Angiogenesis and Left Ventricle Remodeling and Function in Mice With Myocardial Infarction. Molecular Therapy, 2013, 21, 1390-1402.	3.7	127
64	Heart Failure Gene Therapy. Circulation Research, 2013, 113, 792-809.	2.0	61
65	Receptor Tyrosine Kinase-Mediated Angiogenesis. Cold Spring Harbor Perspectives in Biology, 2013, 5, a009183-a009183.	2.3	135
66	Therapeutic Angiogenesis Revisited. Catheterization and Cardiovascular Interventions, 2013, 82, 907-908.	0.7	1
67	Gene therapy for heart disease: molecular targets, vectors and modes of delivery to myocardium. Expert Review of Cardiovascular Therapy, 2013, 11, 999-1013.	0.6	7
68	High Doses of Vascular Endothelial Growth Factor 165 Safely, but Transiently, Improve Myocardial Perfusion in No-Option Ischemic Disease. Human Gene Therapy Methods, 2013, 24, 298-306.	2.1	23
69	G-CSF Induced Arteriogenesis in Humans: Molecular Insights into a Randomized Controlled Trial. Current Vascular Pharmacology, 2013, 11, 38-46.	0.8	19
70	Gene Delivery Strategies Targeting Stable Atheromatous Plaque. Current Pharmaceutical Design, 2013, 19, 1626-1637.	0.9	4
71	VEGF 165 Gene Therapy for Patients with Refractory Angina: Mobilization of Endothelial Progenitor Cells. Arquivos Brasileiros De Cardiologia, 2013, 101, 149-53.	0.3	6
72	Cardiac Angiogenesis: Role of Cardiomyocytes and Macrophages and Possible Therapeutic Approaches. Current Angiogenesis, 2014, 3, 11-18.	0.1	0

#	Article	IF	CITATIONS
73	PGC-1α Induces SPP1 to Activate Macrophages and Orchestrate Functional Angiogenesis in Skeletal Muscle. Circulation Research, 2014, 115, 504-517.	2.0	86
74	Ultrasound-targeted cardiovascular gene therapy. , 2014, , 380-407.		4
75	Cardiovascular regenerative therapeutics via synthetic paracrine factor modified mRNA. Stem Cell Research, 2014, 13, 693-704.	0.3	26
76	Blood vessel repair and regeneration in the ischaemic heart. Open Heart, 2014, 1, e000016.	0.9	33
77	Single Intracoronary Injection of Encapsulated Antagomirâ€92a Promotes Angiogenesis and Prevents Adverse Infarct Remodeling. Journal of the American Heart Association, 2014, 3, e000946.	1.6	76
78	Treatment of refractory angina in patients not suitable for revascularization. Nature Reviews Cardiology, 2014, 11, 78-95.	6.1	116
79	Effect of atorvastatin on the angiogenic responsiveness of coronary endothelial cells in normal and streptozotocin (STZ) induced diabetic rats. Canadian Journal of Physiology and Pharmacology, 2014, 92, 338-349.	0.7	9
80	A systems biology view of blood vessel growth and remodelling. Journal of Cellular and Molecular Medicine, 2014, 18, 1491-1508.	1.6	139
81	The Promise and Challenges of Cardiac Stem Cell Therapy. Seminars in Thoracic and Cardiovascular Surgery, 2014, 26, 44-52.	0.4	16
82	Cell sheet approach for tissue engineering and regenerative medicine. Journal of Controlled Release, 2014, 190, 228-239.	4.8	203
83	Inhibition of intimal hyperplasia via local delivery of vascular endothelial growth factor cDNA nanoparticles in a rabbit model of restenosis induced by abdominal aorta balloon injury. Experimental and Therapeutic Medicine, 2015, 10, 55-61.	0.8	7
84	High-Resolution Harmonics Ultrasound Imaging for Non-Invasive Characterization of Wound Healing in a Pre-Clinical Swine Model. PLoS ONE, 2015, 10, e0122327.	1.1	34
85	Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia?. Case Reports in Oncological Medicine, 2015, 2015, 1-4.	0.2	2
86	New Antianginal Drugs Still Not Available for Clinical Use. , 2015, , 189-234.		0
88	Highly Angiogenic Peptide Nanofibers. ACS Nano, 2015, 9, 860-868.	7.3	140
89	Predictors of Longâ€ŧerm Clinical Endpoints in Patients With Refractory Angina. Journal of the American Heart Association, 2015, 4, .	1.6	61
90	Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation. Cardiovascular Research, 2015, 108, 4-20.	1.8	129
91	VEGF and Angiopoietins Promote Inflammatory Cell Recruitment and Mature Blood Vessel Formation in Murine Sponge/Matrigel Model. Journal of Cellular Biochemistry, 2015, 116, 45-57.	1.2	24

#	Article	IF	CITATIONS
92	Role of copper in regression of cardiac hypertrophy. , 2015, 148, 66-84.		46
93	Synthetic Chemically Modified mRNA (modRNA): Toward a New Technology Platform for Cardiovascular Biology and Medicine. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a014035-a014035.	2.9	45
94	Vasculogenesis and Angiogenesis. , 2016, , 49-65.		15
95	AdVEGF-B ₁₈₆ and AdVEGF-D ^{ΔNΔC} induce angiogenesis and increase perfusion in porcine myocardium. Heart, 2016, 102, 1716-1720.	1.2	30
96	Treatment of hind limb ischemia using angiogenic peptide nanofibers. Biomaterials, 2016, 98, 113-119.	5.7	94
97	Prospect of ultrasound-mediated gene delivery in cardiovascular applications. Expert Opinion on Biological Therapy, 2016, 16, 815-826.	1.4	15
98	Cardiac gene therapy: are we there yet?. Gene Therapy, 2016, 23, 635-648.	2.3	21
99	Intramyocardial Gene Therapy Directed to Hibernating Heart Muscle Using a Combination of Electromechanical Mapping and Positron Emission Tomography. Human Gene Therapy, 2016, 27, 830-834.	1.4	16
100	Therapeutic angiogenesis: angiogenic growth factors for ischemic heart disease. Future Cardiology, 2016, 12, 585-599.	0.5	28
101	Novel Angiogenic Activity and Molecular Mechanisms of ZYZ-803, a Slow-Releasing Hydrogen Sulfide–Nitric Oxide Hybrid Molecule. Antioxidants and Redox Signaling, 2016, 25, 498-514.	2.5	55
102	The genetics of exceptional longevity identifies new druggable targets for vascular protection and repair. Pharmacological Research, 2016, 114, 169-174.	3.1	4
103	Vascularization strategies of engineered tissues and their application in cardiac regeneration. Advanced Drug Delivery Reviews, 2016, 96, 183-194.	6.6	116
104	Gene Therapy in Cardiac Surgery: Clinical Trials, Challenges, and Perspectives. Annals of Thoracic Surgery, 2016, 101, 2407-2416.	0.7	22
105	Metformin improves the angiogenic potential of human CD34+ cells co-incident with downregulating CXCL10 and TIMP1 gene expression and increasing VEGFA under hyperglycemia and hypoxia within a therapeutic window for myocardial infarction. Cardiovascular Diabetology, 2016, 15, 27.	2.7	43
106	Osteoglycin's embracement of VEGF receptor-2 limits angiogenesis and collateralization. Cardiovascular Research, 2017, 113, 10-12.	1.8	2
107	Angiogenic gene therapy in cardiovascular diseases: dream or vision?. European Heart Journal, 2017, 38, ehw547.	1.0	123
108	Concise Review: Mending a Broken Heart: The Evolution of Biological Therapeutics. Stem Cells, 2017, 35, 1131-1140.	1.4	11
109	Advancements in pharmacotherapy for angina. Expert Opinion on Pharmacotherapy, 2017, 18, 457-469.	0.9	4

#	ARTICLE Gene delivery nanoparticles to modulate angiogenesis. Advanced Drug Delivery Reviews, 2017, 119,	IF	CITATIONS
110	20-43.	0.0	01
111	Cardiovascular Gene Therapy: Past, Present, and Future. Molecular Therapy, 2017, 25, 1095-1106.	3.7	141
112	Mean field study of a propagation-turnover lattice model for the dynamics of histone marking. Science China: Physics, Mechanics and Astronomy, 2017, 60, 1.	2.0	0
113	The coronary sinus reducer: clinical evidence and technical aspects. Expert Review of Cardiovascular Therapy, 2017, 15, 47-58.	0.6	23
114	Trials of Angiogenesis Therapy in Patients with Ischemic Heart Disease. , 2017, , 393-421.		0
115	Alternative interventions for refractory angina. Heart, 2017, 103, 1911-1922.	1.2	27
116	Adenoviral intramyocardial VEGF-DΔNΔC gene transfer increases myocardial perfusion reserve in refractory angina patients: a phase I/IIa study with 1-year follow-up. European Heart Journal, 2017, 38, 2547-2555.	1.0	109
117	Translational cardiac stem cell therapy: advancing from first-generation to next-generation cell types. Npj Regenerative Medicine, 2017, 2, 17.	2.5	113
118	Ultrasound-targeted microbubble destruction in gene therapy: A new tool to cure human diseases. Genes and Diseases, 2017, 4, 64-74.	1.5	31
119	Targeting of Magnetic Nanoparticle-coated Microbubbles to the Vascular Wall Empowers Site-specific Lentiviral Gene Delivery <i>in vivo</i> . Theranostics, 2017, 7, 295-307.	4.6	20
120	Comparison of Non-human Primate versus Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Treatment of Myocardial Infarction. Stem Cell Reports, 2018, 10, 422-435.	2.3	49
122	Angiogenic Growth Factors for Coronary Artery Disease: Current Status and Prospects. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 130-141.	1.0	9
123	Non-invasive strategies for stimulating endogenous repair and regenerative mechanisms in the damaged heart. Pharmacological Research, 2018, 127, 33-40.	3.1	12
124	Refractory Angina. , 2018, , 412-431.		3
125	Extracellular Vesicle-Mediated Immune Regulation of Tissue Remodeling and Angiogenesis After Myocardial Infarction. Frontiers in Immunology, 2018, 9, 2799.	2.2	30
126	Microvasculature Recovery by Angiogenesis After Myocardial Infarction. Current Pharmaceutical Design, 2018, 24, 2967-2973.	0.9	33
128	Gene Therapy and Genomic Application in Heart Disease. Translational Bioinformatics, 2018, , 337-374.	0.0	0
129	Holistic Regulation of Angiogenesis with Chinese Herbal Medicines as a New Option for Coronary Artery Disease. Evidence-based Complementary and Alternative Medicine, 2018, 2018, 1-10.	0.5	10

#	Article	IF	CITATIONS
130	Disruption of VEGF Mediated Flkâ€l Signaling Leads to a Gradual Loss of Vessel Health and CardiacÂFunction During Myocardial Infarction: Potential Therapy With Pellinoâ€l. Journal of the American Heart Association, 2018, 7, e007601.	1.6	21
131	Dawn of Epitranscriptomic Medicine. Circulation Genomic and Precision Medicine, 2018, 11, e001927.	1.6	24
132	Mesenchymal Stem Cell-Based Therapy for Cardiovascular Disease: Progress and Challenges. Molecular Therapy, 2018, 26, 1610-1623.	3.7	241
133	Osteoinduction byEx VivoNonviral Bone Morphogenetic Protein Gene Delivery Is Independent of Cell Type. Tissue Engineering - Part A, 2018, 24, 1423-1431.	1.6	4
134	Ultrasound imaging and on-demand therapy of peripheral arterial diseases using H2O2-Activated bubble generating anti-inflammatory polymer particles. Biomaterials, 2018, 179, 175-185.	5.7	41
135	Cardiac Stem Cells: A Plethora of Potential Therapies for Myocardial Regeneration Within Reach. , 2018, , 135-171.		1
136	VEGF-A and VEGF-B Coordinate the Arteriogenesis to Repair the Infarcted Heart with Vagus Nerve Stimulation. Cellular Physiology and Biochemistry, 2018, 48, 433-449.	1.1	30
137	Vascular endothelial growth factor gene transfer therapy for coronary artery disease: A systematic review and metaâ€analysis. Cardiovascular Therapeutics, 2018, 36, e12461.	1.1	11
138	Stem cell and gene-based approaches for cardiac repair. , 2018, , 31-96.		1
139	Gene therapy in cardiovascular diseases: A review of recent updates. Journal of Cellular Biochemistry, 2018, 119, 9645-9654.	1.2	6
140	VEGFâ€A inhibits agonistâ€mediated Ca ²⁺ responses and activation of IK _{Ca} channels in mouse resistance artery endothelial cells. Journal of Physiology, 2018, 596, 3553-3566.	1.3	6
141	Pro―and antiangiogenic therapies: current status and clinical implications. FASEB Journal, 2019, 33, 34-48.	0.2	56
142	From Bench to Clinic: Translation of Cardiovascular Tissue Engineering Products to Clinical Applications. , 2019, , 125-140.		0
143	Intravascular Stem Cell Bioreactor for Prevention of Adverse Remodeling After Myocardial Infarction. Journal of the American Heart Association, 2019, 8, e012351.	1.6	9
145	Local pharmacological induction of angiogenesis: Drugs for cells and cells as drugs. Advanced Drug Delivery Reviews, 2019, 146, 126-154.	6.6	13
146	The Role of the Stem Cells Therapy in the Peripheral Artery Disease. International Journal of Molecular Sciences, 2019, 20, 2233.	1.8	12
147	Gene Therapy in Cardiac Disease. , 2019, , 377-392.		0
148	Combination of <i>Ligusticum Chuanxiong</i> and <i>Radix Paeonia</i> Promotes Angiogenesis in Ischemic Myocardium through Notch Signalling and Mobilization of Stem Cells. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-12.	0.5	11

#	Article	IF	CITATIONS
149	VEGF-A plasma levels are associated with microvascular obstruction in patients with ST-segment elevation myocardial infarction. International Journal of Cardiology, 2019, 291, 19-24.	0.8	20
150	Enrichment of vascular endothelial growth factor secreting mesenchymal stromal cells enhances therapeutic angiogenesis in a mouse model of hind limb ischemia. Cytotherapy, 2019, 21, 433-443.	0.3	11
151	Sequential Bone-Marrow Cell Delivery of VEGFA/S1P Improves Vascularization and Limits Adverse Cardiac Remodeling After Myocardial Infarction in Mice. Human Gene Therapy, 2019, 30, 893-905.	1.4	8
152	Inhibition of TRPA1 Promotes Cardiac Repair in Mice after Myocardial Infarction. Journal of Cardiovascular Pharmacology, 2019, 75, 1.	0.8	14
153	mRNA-Based Protein Replacement Therapy for the Heart. Molecular Therapy, 2019, 27, 785-793.	3.7	101
154	Gene therapy for refractory angina and cell therapy for heart failure: experience of a Brazilian research group. Gene Therapy, 2020, 27, 40-50.	2.3	2
155	Angiogenesis in Patients with Chronic Heart Failure: Focus on Endothelial Vascular Growth Factor, Pentraxin-3 and Transforming Growth Factor Beta. Rational Pharmacotherapy in Cardiology, 2020, 16, 439-448.	0.3	0
156	Growth factor therapy for cardiac repair: an overview of recent advances and future directions. Biophysical Reviews, 2020, 12, 805-815.	1.5	18
157	Progress of Gene Therapy in Cardiovascular Disease. Hypertension, 2020, 76, 1038-1044.	1.3	16
158	Modified mRNA as a Therapeutic Tool for the Heart. Cardiovascular Drugs and Therapy, 2020, 34, 871-880.	1.3	30
159	Gene Therapy for the Heart Lessons Learned and Future Perspectives. Circulation Research, 2020, 126, 1394-1414.	2.0	81
160	Deletion of newly described pro-survival molecule Pellino-1 increases oxidative stress, downregulates cIAP2/NF-κB cell survival pathway, reduces angiogenic response, and thereby aggravates tissue function in mouse ischemic models. Basic Research in Cardiology, 2020, 115, 45.	2.5	18
161	MicroRNA-24-3p Targets Notch and Other Vascular Morphogens to Regulate Post-ischemic Microvascular Responses in Limb Muscles. International Journal of Molecular Sciences, 2020, 21, 1733.	1.8	17
162	Pre-culture of mesenchymal stem cells within RGD-modified hyaluronic acid hydrogel improves their resilience to ischaemic conditions. Acta Biomaterialia, 2020, 107, 78-90.	4.1	22
163	Oxidative Stress and New Pathogenetic Mechanisms in Endothelial Dysfunction: Potential Diagnostic Biomarkers and Therapeutic Targets. Journal of Clinical Medicine, 2020, 9, 1995.	1.0	79
164	Coronary vessel formation in development and disease: mechanisms and insights for therapy. Nature Reviews Cardiology, 2020, 17, 790-806.	6.1	37
166	Cardiac Regeneration and Repair: From Mechanisms to Therapeutic Strategies. Learning Materials in Biosciences, 2020, , 187-211.	0.2	3
167	Pulsed Electromagnetic Fields Increase Angiogenesis and Improve Cardiac Function After Myocardial Ischemia in Mice. Circulation Journal, 2020, 84, 186-193.	0.7	14

ARTICLE IF CITATIONS # Clinical Safety Profile of Transendocardial Catheter Injection Systems: A Plea for Uniform Reporting. 0.3 5 168 Cardiovascular Revascularization Medicine, 2021, 22, 100-108. Imaging of Gene and Cell-Based Therapies: Basis and Clinical Trials., 2021, , 1539-1587. 170 Cardiotoxic effects of angiogenesis inhibitors. Clinical Science, 2021, 135, 71-100. 46 1.8 Therapeutic Approaches for the No-Option Refractory Angina Patient. Circulation: Cardiovascular 171 1.4 Interventions, 2021, 14, e009002. The vasculature: a therapeutic target in heart failure?. Cardiovascular Research, 2022, 118, 53-64. 172 1.8 26 Gene therapy for ischaemic heart disease and heart failure. Journal of Internal Medicine, 2021, 290, 2.7 24 567-582. Commentary: Can the new synthetic adeno-associated virus vector deliver the promise of cardiac gene 174 0.4 2 therapy?. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, e446-e447. A novel imidazolinone metforminâ
€methylglyoxal metabolite promotes endothelial cell angiogenesis via the eNOS/HIFâ
€1α pathway. FASEB Journal, 2021, 35, e21645. 0.2 Mesenchymal Stem Cells Pretreatment With Stromal-Derived Factor-1 Alpha Augments Cardiac 176 Function and Angiogenesis in Infarcted Myocardium. American Journal of the Medical Sciences, 2021, 0.4 9 361, 765-775. An optimal non-viral gene transfer method for genetically modifying porcine bone marrow-derived endothelial progenitor cells for experimental therapeutics. Science Progress, 2021, 104, 1.0 003685042110241. Therapeutic angiogenesis in coronary artery disease: a review of mechanisms and current approaches. 178 1.9 11 Expert Opinion on Investigational Drugs, 2021, 30, 947-963. Citrate-Saline-Formulated mRNA Delivery into the Heart Muscle with an Electromechanical Mapping and Injection Catheter Does Not Lead to Therapeutic Effects in a Porcine Chronic Myocardial Ischemia 179 1.4 Model. Human Gene Therapy, 2021, 32, 1295-1307. Long-term safety and efficacy of intramyocardial adenovirus-mediated VEGF-DΔNΔC gene therapy 180 2.3 13 eight-year follow-up of phase I KAT301 study. Gene Therapy, 2022, 29, 289-293. Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): 1.2 Rationale, design, and clinical considerations. American Heart Journal, 2021, 241, 38-49. Therapeutic Angiogenesis: Translational and Clinical Experience. Reference Series in Biomedical 182 0.1 0 Engineering, 2021, , 101-144. Cardiovascular Gene Therapy., 2013, , 737-751. Direct Myocardial Injection of Vectors. Methods in Molecular Biology, 2017, 1521, 237-248. 184 0.4 5 Therapeutic Angiogenesis for Vascular Diseases., 2011, , .

	Charlow	LPORT	
#	ARTICLE	IF	CITATIONS
186	Management of refractory angina: an update. European Heart Journal, 2021, 42, 269-283.	1.0	30
187	MicroRNA-377 Regulates Mesenchymal Stem Cell-Induced Angiogenesis in Ischemic Hearts by Targeting VEGF. PLoS ONE, 2014, 9, e104666.	1.1	70
188	The Use of Gene Therapy for Ablation of Atrial Fibrillation. Arrhythmia and Electrophysiology Review, 2014, 3, 139.	1.3	17
189	Evaluation of Gene and Cell-Based Therapies for Cardiac Regeneration. Current Stem Cell Research and Therapy, 2013, 8, 304-312.	0.6	9
190	Restoration of Heart Function Using Transplantation of Human Umbilical Cord Matrix-Derived Cardiomyocytes and Vascular Endothelial Growth Factor. The Open Tissue Engineering and Regenerative Medicine Journal, 2013, 6, 26-36.	2.6	1
191	Terapia gênica para cardiopatia isquêmica. Brazilian Journal of Cardiovascular Surgery, 2011, 26, 635-646.	0.2	9
192	Regenerative Medicine and Angiogenesis; Focused on Cardiovascular Disease. Advanced Pharmaceutical Bulletin, 2021, , .	0.6	2
193	Safe and Effective Vascular Endothelial Cell Growth Factor (VEGF)-based Therapeutic Angiogenesis for Ischemic Stroke: Insights from Preclinical Trials. , 2010, , 169-212.		1
194	Angiogenic Cytokine Therapy for Ischemic Heart Disease. , 2011, , 251-277.		0
195	Cell-Based Gene Therapies and Stem Cells for Regeneration of Ischemic Tissues. , 0, , .		0
196	Refractory Angina. , 2012, , 431-443.		0
197	Trials of Angiogenesis Therapy in Patients with Ischemic Heart Disease. , 2013, , 313-334.		2
198	Angiogenesis in Myocardial Ischemia. , 2013, , 261-283.		2
199	Safety of Direct Cardiac Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector cDNA/Genomic Hybrid Expressing All Three Major Isoforms of Human Vascular Endothelial Growth Factor, to the Ischemic Myocardium of Rats. Human Gene Therapy Clinical Development, 0, , 130514071334005.	3.2	0
200	Outcomes of Middle Cardiac Vein Arterialization via Internal Mammary/Thoracic Artery Anastomosis. PLoS ONE, 2013, 8, e80963.	1.1	0
201	PLGA Nano- and Microparticles for VEGF Delivery. , 2016, , 445-478.		0
202	Therapeutic Angiogenesis: Translational and Clinical Experience. , 2021, , 1-45.		1
203	Gene and protein therapy approaches to cardiac neovascularization and protection from ischemia. , 2020, , 649-666.		0

ARTICLE IF CITATIONS Molecular therapies forÂbradyarrhythmias. , 2020, , 811-840. 204 0 Therapeutic angiogenesis promotes efficacy of human umbilical cord matrix stem cell transplantation 1.0 in cardiac repair. Iranian Journal of Basic Médical Sciences, 2015, 18, 563-70. Fibroblast transition to an endothelial "trans―state improves cell reprogramming efficiency. 206 1.6 8 Scientific Reports, 2021, 11, 22605. Immunoengineering strategies to enhance vascularization and tissue regeneration. Advanced Drug 208 Delivery Reviews, 2022, 184, 114233. Coronary vessel formation in development and regeneration: origins and mechanisms. Journal of 209 0.9 5 Molecular and Cellular Cardiology, 2022, 167, 67-82. Characteristics and Outcomes of Clinical Trials on Gene Therapy in Noncongenital Cardiovascular Diseases: Cross-sectional Study of Three Clinical Trial Registries. JMIR Formative Research, 2022, 6, e33893. Endothelial plasticity drives aberrant vascularization and impedes cardiac repair after myocardial 211 9 infarction., 2022, 1, 372-388. Signaling cascades in the failing heart and emerging therapeutic strategies. Signal Transduction and 7.1 Targeted Therapy, 2022, 7, 134. KANK4 Promotes Arteriogenesis by Potentiating VEGFR2 Signaling in a TALIN-1–Dependent Manner. 213 2 1.1 Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 772-788. Angiogenic Hydrogels to Accelerate Early Wound Healing. Macromolecular Bioscience, 2022, 22, 2.1 e2200067. Biomimetic virus-based soft niche for ischemic diseases. Biomaterials, 2022, 288, 121747. 216 5.78 Endocardial Gene Delivery Using NOGA Catheter System. Methods in Molecular Biology, 2022, , 179-187. 0.4 Current knowledge on the tissue distribution of mRNA nanocarriers for therapeutic protein 218 2.6 3 expression. Biomaterials Science, 2022, 10, 6077-6115. Deciphering the Basis of Molecular Biology of Selected Cardiovascular Diseases: A View on Network Medicine. International Journal of Molecular Sciences, 2022, 23, 11421. 1.8 Future Impact of mRNA Therapy on Cardiovascular Diseases. Methodist DeBakey Cardiovascular 220 0.51 Journal, 2022, 18, 64-73. Modified mRNA Therapeutics for Heart Diseases. International Journal of Molecular Sciences, 2022, 23, 221 1.8 15514. Growth factor for therapeutic angiogenesis in ischemic heart disease: A meta-analysis of randomized 222 1.8 1 controlled trials. Frontiers in Cell and Developmental Biology, 0, 10, . Proangiogenic Growth Factor Therapy for the Treatment of Refractory Angina: A Meta-analysis. , 2023, 223 2, 100527.

#	Article	IF	CITATIONS
224	Progress in Clinical Gene Therapy for Cardiac Disorders. Molecular Diagnosis and Therapy, 2023, 27, 179-191.	1.6	3
225	Therapeutic angiogenesis and tissue revascularization in ischemic vascular disease. Journal of Biological Engineering, 2023, 17, .	2.0	2